author-photo

Kelsey Alvarez

Memorial Sloan Kettering Cancer Center

5

Papers

34

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

2020 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (5)
EARLY RESULTS OF A PHASE II STUDY OF COMBINED RUXOLITINIB AND THALIDOMIDE IN PATIENTS WITH MYELOFIBROSIS: PS1467

2019
Show All
- Source
- Cite
- Save
Citations (2)
Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents

2018 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study

2018 Blood
Show All
- Source
- Cite
- Save
Citations (6)